For the twelve months ended Sep 30, 2026, Aurinia Pharmaceuticals Inc reported $321.74M of revenue and $314.27M of net income.
AUPH revenue was $83.70M in fiscal Q3 2026 (ended Sep 30, 2026), up 13.9% from a year earlier and up 0.6% from the prior quarter. For the full fiscal 2025 it was $283.06M, up 20.4% from fiscal 2024. Compound annual growth was +41.4% over 5 years. It rose in 7 of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.
AUPH net income was $31.70M in fiscal Q3 2026 (ended Sep 30, 2026), up 0.5% from a year earlier and down 15.3% from the prior quarter. For the full fiscal 2025 it was $287.20M, up about 50-fold from fiscal 2024. Fiscal 2025 is the highest of the 10 fiscal years on file.
AUPH diluted EPS was $0.23 in fiscal Q3 2026 (ended Sep 30, 2026), up 0.0% from a year earlier and down 17.9% from the prior quarter. For the full fiscal 2025 it was $2.07, up about 52-fold from fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M | $318.0K | $463.0K | $418.0K | $173.0K |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M | $0 | $0 | - | - | - |
| Gross profit | $250.39M | $206.88M | $161.37M | $128.37M | $44.51M | $50.12M | $318.0K | - | - | - |
| Research and development | $32.51M | $20.79M | $49.64M | $44.99M | $51.14M | $50.33M | $52.87M | $41.38M | $33.93M | $14.53M |
| Selling, general and admin | $101.79M | $172.03M | $195.04M | $196.37M | $173.50M | $97.30M | $22.30M | $13.69M | $12.10M | $6.97M |
| Operating income | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M | -$90.94M | -$55.24M | -$46.87M | -$25.03M |
| Interest expense | $4.33M | $4.83M | $2.77M | $0 | $0 | - | $39.0K | $0 | - | - |
| Pre-tax income | $114.16M | $7.45M | -$77.47M | -$106.35M | -$180.21M | -$102.77M | -$88.24M | -$53.01M | -$70.79M | - |
| Income tax | -$173.04M | $1.70M | $551.0K | $1.83M | $760.0K | -$94.0K | $144.0K | $73.0K | $0 | $0 |
| Net income | $287.20M | $5.75M | -$78.02M | -$108.18M | -$180.97M | -$102.68M | -$88.39M | -$53.08M | -$70.79M | -$23.30M |
| EPS, basic | $2.14 | $0.04 | -$0.54 | -$0.76 | -$1.40 | -$0.87 | -$0.95 | -$0.63 | - | - |
| EPS, diluted | $2.07 | $0.04 | -$0.54 | -$0.76 | -$1.40 | -$0.87 | -$0.95 | -$0.63 | - | - |
| Diluted shares | 138.7M | 146.2M | 143.2M | 141.9M | 129.4M | 118.5M | 93.0M | 84.8M | 76.9M | 35.3M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $80.21M | $83.43M | $48.76M | $94.17M | $231.90M | $272.35M | $306.02M | $117.97M | $165.63M | $39.65M |
| Inventory | $45.69M | $39.23M | $39.70M | $24.75M | $19.33M | $13.93M | $0 | - | - | - |
| Current assets | $491.97M | $446.60M | $424.80M | $442.54M | $513.32M | $419.43M | $315.14M | $132.85M | $175.25M | $41.42M |
| Total assets | $751.59M | $550.64M | $548.06M | $470.86M | $543.37M | $463.66M | $324.30M | $145.86M | $189.85M | $57.00M |
| Current liabilities | $93.72M | $97.76M | $77.19M | $46.11M | $40.65M | $32.00M | $11.29M | $7.26M | $8.15M | $7.93M |
| Total liabilities | $170.26M | $173.17M | $170.11M | $65.42M | $64.28M | $55.91M | $25.70M | $33.29M | $24.10M | $21.05M |
| Shareholders' equity | $581.33M | $377.48M | $377.95M | $405.44M | $479.09M | $407.75M | $298.60M | $135.72M | $177.92M | $35.95M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $135.66M | $44.39M | -$33.46M | -$79.53M | -$157.69M | -$69.86M | -$63.59M | -$51.61M | -$41.17M | -$18.71M |
| Capital expenditures | - | - | - | - | - | - | $87.0K | $30.0K | $25.0K | $15.0K |
| Free cash flow | - | - | - | - | - | - | -$63.67M | -$51.64M | -$41.19M | -$18.73M |
| Investing cash flow | -$32.77M | $39.26M | -$6.71M | -$60.63M | -$103.87M | -$158.19M | $7.78M | -$65.0K | -$8.00M | $9.99M |
| Financing cash flow | -$106.11M | -$49.09M | -$5.13M | $2.43M | $221.11M | $194.38M | $243.85M | $4.01M | $175.15M | $42.62M |
| Share repurchases | $98.16M | $40.24M | $0 | $0 | - | - | - | - | - | - |
| Stock-based compensation | $14.68M | $31.60M | $45.31M | $32.30M | $31.24M | $17.45M | $7.41M | $6.86M | $4.24M | $1.38M |
| Depreciation and amortization | $19.45M | $19.45M | $11.65M | $2.71M | $2.76M | $1.37M | - | - | - | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 20.4% | 34.0% | 31.0% | 193.9% | -9.0% | 15660.4% | -31.3% | 10.8% | 141.6% | - |
| Net income growth, YoY | 4893.1% | - | - | - | - | - | - | - | - | - |
| EPS growth, YoY | 5075.0% | - | - | - | - | - | - | - | - | - |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | - | - | - |
| Operating margin | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -11930.9% | -11212.4% | -14466.5% |
| Net margin | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -11464.1% | -16935.9% | -13465.3% |
| Free cash flow margin | - | - | - | - | - | - | -20022.6% | -11153.6% | -9855.0% | -10825.4% |
| Return on equity | 49.4% | 1.5% | -20.6% | -26.7% | -37.8% | -25.2% | -29.6% | -39.1% | -39.8% | -64.8% |
| Return on assets | 38.2% | 1.0% | -14.2% | -23.0% | -33.3% | -22.1% | -27.3% | -36.4% | -37.3% | -40.9% |
| Current ratio | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.70M | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M | $62.47M | $59.87M | $67.77M | $57.19M | $50.30M | $45.09M |
| Cost of revenue | $8.31M | $6.55M | $6.50M | $8.80M | $8.18M | $7.12M | $8.57M | $5.55M | $6.04M | $8.91M | $7.75M | $5.39M |
| Gross profit | $75.39M | $76.67M | $71.20M | $68.31M | $65.29M | $62.89M | $53.89M | $54.31M | $61.74M | $48.28M | $42.55M | $39.70M |
| Research and development | $16.61M | $13.05M | $7.47M | $10.89M | $8.44M | $7.43M | $5.74M | $8.11M | $3.05M | $4.08M | $5.55M | $10.23M |
| Selling, general and admin | $24.68M | $23.51M | $22.03M | $29.25M | $26.18M | $26.02M | $20.34M | $37.03M | $42.37M | $44.93M | $47.70M | $50.07M |
| Operating income | $35.36M | $46.34M | $41.42M | $33.24M | $29.75M | $20.08M | $21.85M | -$1.67M | $11.75M | -$1.51M | -$13.25M | -$29.67M |
| Interest expense | $867.0K | $948.0K | $1.01M | $1.05M | $1.10M | $1.12M | $1.07M | $1.15M | $1.21M | $1.20M | $1.28M | $1.31M |
| Pre-tax income | $38.72M | $48.79M | $43.92M | $35.69M | $31.96M | $22.16M | $24.35M | $1.17M | $14.81M | $1.48M | -$10.01M | -$26.42M |
| Income tax | $7.01M | $11.37M | $9.57M | -$175.10M | $411.0K | $643.0K | $1.00M | -$256.0K | $457.0K | $756.0K | $739.0K | $459.0K |
| Net income | $31.70M | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | $23.34M | $1.43M | $14.35M | $722.0K | -$10.75M | -$26.88M |
| EPS, basic | $0.24 | $0.29 | $0.26 | $1.60 | $0.24 | $0.16 | $0.17 | $0.01 | $0.10 | $0.01 | -$0.07 | -$0.19 |
| EPS, diluted | $0.23 | $0.28 | $0.25 | $1.53 | $0.23 | $0.16 | $0.16 | $0.01 | $0.10 | $0.01 | -$0.07 | -$0.19 |
| Diluted shares | 135.2M | 133.5M | 137.6M | - | 136.0M | 137.5M | 143.2M | - | 145.7M | 144.1M | 144.0M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.79M | $179.73M | $40.75M | $80.21M | $72.89M | $52.91M | $66.11M | $83.43M | $36.63M | $33.27M | $63.91M | $48.76M |
| Inventory | $43.73M | $45.15M | $46.41M | $45.69M | $44.79M | $46.50M | $46.20M | $39.23M | $38.71M | $38.85M | $39.76M | $39.70M |
| Current assets | $587.89M | $541.32M | $480.24M | $491.97M | $438.74M | $408.97M | $405.76M | $446.60M | $440.46M | $409.67M | $398.22M | $424.80M |
| Total assets | $825.70M | $792.26M | $724.00M | $751.59M | $527.53M | $502.56M | $504.85M | $550.64M | $549.36M | $523.53M | $516.63M | $548.06M |
| Current liabilities | $96.00M | $99.89M | $86.56M | $93.72M | $76.22M | $78.27M | $68.41M | $97.76M | $78.61M | $76.90M | $71.05M | $77.19M |
| Total liabilities | $168.19M | $177.40M | $156.37M | $170.26M | $161.76M | $167.26M | $154.66M | $173.17M | $161.36M | $158.91M | $157.16M | $170.11M |
| Shareholders' equity | $657.52M | $614.86M | $567.63M | $581.33M | $365.77M | $335.30M | $350.19M | $377.48M | $388.00M | $364.62M | $359.48M | $377.95M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $46.37M | $52.57M | $32.56M | $45.67M | $44.45M | $44.24M | $1.30M | $30.11M | $17.03M | $15.84M | -$18.60M | $14.31M |
| Investing cash flow | -$175.73M | $81.45M | -$18.08M | -$36.76M | -$13.77M | -$13.27M | $31.03M | $39.22M | -$10.57M | -$38.62M | $49.23M | -$6.26M |
| Financing cash flow | -$4.32M | $4.81M | -$53.69M | -$1.89M | -$10.49M | -$44.39M | -$49.34M | -$23.05M | -$2.72M | -$8.27M | -$15.05M | -$5.58M |
| Share repurchases | $0 | $38.72M | $36.16M | $0 | $8.67M | $42.56M | $46.92M | $21.80M | $0 | $6.13M | $12.30M | $0 |
| Stock-based compensation | $6.12M | $2.84M | -$866.0K | $6.73M | $5.92M | $5.44M | -$3.41M | $8.95M | $8.33M | $8.59M | $5.74M | $11.77M |
| Depreciation and amortization | $4.84M | $4.83M | $4.82M | $4.86M | $4.87M | $4.86M | $4.86M | $4.86M | $4.89M | $4.84M | $4.85M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 13.9% | 18.9% | 24.4% | 28.8% | 8.4% | 22.4% | 24.2% | 32.8% | 24.3% | 37.8% | 46.2% | 58.6% |
| Net income growth, YoY | 0.5% | 73.9% | 47.2% | 14651.2% | 119.9% | 2879.6% | - | - | - | - | - | - |
| EPS growth, YoY | 0.0% | 75.0% | 56.3% | 15200.0% | 130.0% | 1500.0% | - | - | - | - | - | - |
| Gross margin | 90.1% | 92.1% | 91.6% | 88.6% | 88.9% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% |
| Operating margin | 42.3% | 55.7% | 53.3% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% | -2.6% | -26.3% | -65.8% |
| Net margin | 37.9% | 45.0% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | -21.4% | -59.6% |
| Current ratio | 6.12 | 5.42 | 5.55 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 |
Source: XBRL data Aurinia Pharmaceuticals Inc files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AUPH | $321.74M | +21.0% | $314.27M | 97.7% | $2.21B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |